6.67
price down icon12.12%   -0.92
after-market After Hours: 6.88 0.21 +3.15%
loading
Rocket Pharmaceuticals Inc stock is traded at $6.67, with a volume of 6.51M. It is down -12.12% in the last 24 hours and down -29.42% over the past month.
See More
Previous Close:
$7.59
Open:
$7.21
24h Volume:
6.51M
Relative Volume:
4.24
Market Cap:
$930.88M
Revenue:
-
Net Income/Loss:
$-258.08M
P/E Ratio:
-2.4255
EPS:
-2.75
Net Cash Flow:
$-202.32M
1W Performance:
-23.60%
1M Performance:
-29.42%
6M Performance:
-63.89%
1Y Performance:
-75.24%
1-Day Range:
Value
$6.26
$7.275
1-Week Range:
Value
$6.26
$8.80
52-Week Range:
Value
$6.26
$26.99

Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile

Name
Name
Rocket Pharmaceuticals Inc
Name
Phone
646-440-9100
Name
Address
350 FIFTH AVENUE, NEW YORK, NY
Name
Employee
0
Name
Twitter
@rocketpharma
Name
Next Earnings Date
2024-11-04
Name
Latest SEC Filings
Name
RCKT's Discussions on Twitter

Compare RCKT with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
RCKT
Rocket Pharmaceuticals Inc
6.67 930.88M 0 -258.08M -202.32M -2.75
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.82 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
634.23 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
591.87 36.10B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
270.02 35.03B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
272.17 28.24B 3.81B -644.79M -669.77M -6.24

Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-12-25 Initiated BMO Capital Markets Outperform
Dec-30-24 Initiated Wedbush Outperform
Dec-18-24 Initiated Jefferies Buy
Oct-16-24 Initiated Scotiabank Sector Outperform
Apr-02-24 Initiated Goldman Neutral
Oct-24-23 Initiated Cantor Fitzgerald Overweight
Feb-01-23 Initiated Morgan Stanley Overweight
Nov-08-22 Initiated Canaccord Genuity Buy
Nov-01-22 Initiated BTIG Research Buy
Jul-08-22 Initiated Raymond James Outperform
Oct-20-21 Resumed Cowen Outperform
Mar-02-21 Initiated Stifel Buy
Feb-18-21 Initiated Needham Buy
Dec-16-20 Initiated UBS Buy
Dec-08-20 Downgrade Oppenheimer Outperform → Perform
Jul-02-20 Initiated JP Morgan Overweight
Jun-25-20 Resumed BofA/Merrill Buy
Jun-01-20 Resumed Oppenheimer Outperform
Nov-06-19 Initiated Chardan Capital Markets Buy
Sep-26-19 Initiated Piper Jaffray Overweight
Apr-23-19 Initiated Robert W. Baird Outperform
Mar-15-19 Initiated BofA/Merrill Buy
Feb-05-19 Initiated Oppenheimer Outperform
Sep-13-18 Initiated Ladenburg Thalmann Buy
Jul-10-18 Initiated William Blair Outperform
View All

Rocket Pharmaceuticals Inc Stock (RCKT) Latest News

pulisher
Mar 30, 2025

Rocket Pharmaceuticals (NASDAQ:RCKT) Reaches New 1-Year LowHere's Why - MarketBeat

Mar 30, 2025
pulisher
Mar 29, 2025

Swiss National Bank Has $1.93 Million Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World

Mar 29, 2025
pulisher
Mar 26, 2025

Is Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) the Best US Stock Under $10 to Buy Right Now? - Yahoo Finance

Mar 26, 2025
pulisher
Mar 24, 2025

Rocket Pharmaceuticals’ SWOT analysis: gene therapy stock poised for growth amid challenges By Investing.com - Investing.com South Africa

Mar 24, 2025
pulisher
Mar 24, 2025

Rocket Pharmaceuticals’ SWOT analysis: gene therapy stock poised for growth amid challenges - Investing.com India

Mar 24, 2025
pulisher
Mar 24, 2025

Cantor Fitzgerald maintains Overweight on Rocket Pharmaceuticals stock By Investing.com - Investing.com Canada

Mar 24, 2025
pulisher
Mar 24, 2025

Charles Schwab Investment Management Inc. Has $8.25 Million Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World

Mar 24, 2025
pulisher
Mar 22, 2025

(RCKT) Technical Pivots with Risk Controls - news.stocktradersdaily.com

Mar 22, 2025
pulisher
Mar 22, 2025

PNC Financial Services Group Inc. Increases Stock Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World

Mar 22, 2025
pulisher
Mar 21, 2025

Bank of New York Mellon Corp Buys 9,949 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World

Mar 21, 2025
pulisher
Mar 20, 2025

Fanconi Anemia Pipeline 2025: FDA Approvals and Clinical Trials - openPR.com

Mar 20, 2025
pulisher
Mar 19, 2025

What technical indicators reveal about RCKT stock - US Post News

Mar 19, 2025
pulisher
Mar 18, 2025

Steward Partners Investment Advisory LLC Has $84,000 Stock Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World

Mar 18, 2025
pulisher
Mar 16, 2025

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Purchased by Arizona State Retirement System - Defense World

Mar 16, 2025
pulisher
Mar 14, 2025

BMO Capital Markets Begins Coverage on Rocket Pharmaceuticals (NASDAQ:RCKT) - Defense World

Mar 14, 2025
pulisher
Mar 14, 2025

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World

Mar 14, 2025
pulisher
Mar 12, 2025

(RCKT) Investment Analysis and Advice - news.stocktradersdaily.com

Mar 12, 2025
pulisher
Mar 12, 2025

BMO Capital Initiates Coverage on Rocket Pharmaceuticals With Outperform Rating, $50 Price Target - Marketscreener.com

Mar 12, 2025
pulisher
Mar 12, 2025

BMO Capital Initiates Coverage of Rocket Pharmaceuticals (RCKT) with Outperform Recommendation - Nasdaq

Mar 12, 2025
pulisher
Mar 12, 2025

Rocket Pharmaceuticals: A Buy Rating for Its Pioneering Gene Therapy Approach and Promising Pipeline - TipRanks

Mar 12, 2025
pulisher
Mar 11, 2025

BMO Capital sets $50 target for Rocket Pharmaceuticals stock By Investing.com - Investing.com Canada

Mar 11, 2025
pulisher
Mar 08, 2025

Private Advisor Group LLC Acquires Shares of 13,199 Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World

Mar 08, 2025
pulisher
Mar 06, 2025

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Sold by New York State Common Retirement Fund - Defense World

Mar 06, 2025
pulisher
Mar 06, 2025

Rhumbline Advisers Has $1.25 Million Stock Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World

Mar 06, 2025
pulisher
Mar 06, 2025

Research Analysts Set Expectations for RCKT FY2025 Earnings - Defense World

Mar 06, 2025
pulisher
Mar 05, 2025

Rocket Pharmaceuticals, Inc. (RCKT): A Bull Case Theory - Insider Monkey

Mar 05, 2025
pulisher
Mar 04, 2025

2025 Market Prospects of Adeno-Associated Virus Vectors in Gene Therapy Pipeline: 200 Pipeline Drugs and the Strategic Workings of 180+ Companies - GlobeNewswire Inc.

Mar 04, 2025
pulisher
Mar 04, 2025

Handelsbanken Fonder AB Has $290,000 Stock Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World

Mar 04, 2025
pulisher
Mar 04, 2025

Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target Cut to $15.00 by Analysts at The Goldman Sachs Group - Defense World

Mar 04, 2025
pulisher
Mar 04, 2025

Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target Raised to $52.00 at Scotiabank - Defense World

Mar 04, 2025
pulisher
Mar 04, 2025

Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target Lowered to $36.00 at Canaccord Genuity Group - Defense World

Mar 04, 2025
pulisher
Mar 04, 2025

Rocket Pharmaceuticals (NASDAQ:RCKT) Sets New 1-Year Low on Analyst Downgrade - Defense World

Mar 04, 2025
pulisher
Mar 03, 2025

Rocket Pharmaceuticals Inc (NASDAQ: RCKT)’s Stock Adds 0.53%, Making It A Good Investment - Stocks Register

Mar 03, 2025
pulisher
Mar 03, 2025

Scotiabank raises Rocket Pharmaceuticals target to $52 - Investing.com

Mar 03, 2025
pulisher
Mar 03, 2025

What is William Blair’s Estimate for RCKT Q1 Earnings? - Defense World

Mar 03, 2025
pulisher
Mar 03, 2025

Needham & Company LLC Cuts Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target to $42.00 - Defense World

Mar 03, 2025
pulisher
Mar 03, 2025

What is Leerink Partnrs’ Estimate for RCKT Q2 Earnings? - Defense World

Mar 03, 2025
pulisher
Mar 03, 2025

Chardan Capital Cuts Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target to $54.00 - Defense World

Mar 03, 2025
pulisher
Mar 02, 2025

Rocket Pharmaceuticals price target lowered to $15 from $29 at Goldman Sachs - MSN

Mar 02, 2025
pulisher
Mar 02, 2025

When Will Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Turn A Profit? - Yahoo Finance Australia

Mar 02, 2025
pulisher
Mar 01, 2025

Decoding Rocket Pharmaceuticals Inc (RCKT): A Strategic SWOT Ins - GuruFocus

Mar 01, 2025
pulisher
Mar 01, 2025

Rocket Pharmaceuticals Q4 Loss Narrower Than Estimates, Pipeline in Focus - MSN

Mar 01, 2025
pulisher
Feb 28, 2025

Rocket Pharmaceuticals Advances Gene Therapy Pipeline - TipRanks

Feb 28, 2025
pulisher
Feb 28, 2025

Rocket Pharmaceuticals (NASDAQ:RCKT) Posts Earnings Results, Beats Estimates By $0.06 EPS - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Rocket Pharmaceuticals (NASDAQ:RCKT) Sets New 12-Month LowHere's What Happened - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Promising Outlook for Rocket Pharmaceuticals: Buy Rating Reiterated with $32 Price Target - TipRanks

Feb 28, 2025
pulisher
Feb 28, 2025

Rocket Pharmaceuticals Rings the Nasdaq Stock Market Opening Bell - Nasdaq

Feb 28, 2025
pulisher
Feb 28, 2025

Rocket Pharmaceuticals Rings the Opening Bell - Nasdaq

Feb 28, 2025
pulisher
Feb 28, 2025

Cantor Fitzgerald cuts Rocket Pharmaceuticals target to $50 By Investing.com - Investing.com Canada

Feb 28, 2025
pulisher
Feb 28, 2025

Rocket Pharmaceuticals price target lowered to $54 from $62 at Chardan - TipRanks

Feb 28, 2025
pulisher
Feb 28, 2025

Rocket Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com

Feb 28, 2025

Rocket Pharmaceuticals Inc Stock (RCKT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$70.69
price down icon 1.05%
$76.29
price down icon 2.18%
$31.13
price down icon 0.77%
$19.29
price down icon 5.07%
$91.06
price down icon 4.10%
biotechnology ONC
$272.17
price up icon 1.79%
Cap:     |  Volume (24h):